These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
607 related articles for article (PubMed ID: 24225019)
1. PARP Inhibitors for BRCA1/2 mutation-associated and BRCA-like malignancies. Lee JM; Ledermann JA; Kohn EC Ann Oncol; 2014 Jan; 25(1):32-40. PubMed ID: 24225019 [TBL] [Abstract][Full Text] [Related]
2. Enhancement of synthetic lethality via combinations of ABT-888, a PARP inhibitor, and carboplatin in vitro and in vivo using BRCA1 and BRCA2 isogenic models. Clark CC; Weitzel JN; O'Connor TR Mol Cancer Ther; 2012 Sep; 11(9):1948-58. PubMed ID: 22778154 [TBL] [Abstract][Full Text] [Related]
3. Advances in PARP inhibitors for the treatment of breast cancer. Dizdar O; Arslan C; Altundag K Expert Opin Pharmacother; 2015; 16(18):2751-8. PubMed ID: 26485111 [TBL] [Abstract][Full Text] [Related]
4. Evaluation of candidate biomarkers to predict cancer cell sensitivity or resistance to PARP-1 inhibitor treatment. Oplustilova L; Wolanin K; Mistrik M; Korinkova G; Simkova D; Bouchal J; Lenobel R; Bartkova J; Lau A; O'Connor MJ; Lukas J; Bartek J Cell Cycle; 2012 Oct; 11(20):3837-50. PubMed ID: 22983061 [TBL] [Abstract][Full Text] [Related]
5. Use of poly ADP-ribose polymerase [PARP] inhibitors in cancer cells bearing DDR defects: the rationale for their inclusion in the clinic. Cerrato A; Morra F; Celetti A J Exp Clin Cancer Res; 2016 Nov; 35(1):179. PubMed ID: 27884198 [TBL] [Abstract][Full Text] [Related]
6. The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial. Sandhu SK; Schelman WR; Wilding G; Moreno V; Baird RD; Miranda S; Hylands L; Riisnaes R; Forster M; Omlin A; Kreischer N; Thway K; Gevensleben H; Sun L; Loughney J; Chatterjee M; Toniatti C; Carpenter CL; Iannone R; Kaye SB; de Bono JS; Wenham RM Lancet Oncol; 2013 Aug; 14(9):882-92. PubMed ID: 23810788 [TBL] [Abstract][Full Text] [Related]
7. New Targeted Agents in Gynecologic Cancers: Synthetic Lethality, Homologous Recombination Deficiency, and PARP Inhibitors. Liu FW; Tewari KS Curr Treat Options Oncol; 2016 Mar; 17(3):12. PubMed ID: 26931795 [TBL] [Abstract][Full Text] [Related]
8. PARP inhibitors for BRCA1/2-mutated and sporadic ovarian cancer: current practice and future directions. Konecny GE; Kristeleit RS Br J Cancer; 2016 Nov; 115(10):1157-1173. PubMed ID: 27736844 [TBL] [Abstract][Full Text] [Related]
9. Beyond Breast and Ovarian Cancers: PARP Inhibitors for BRCA Mutation-Associated and BRCA-Like Solid Tumors. O'Sullivan CC; Moon DH; Kohn EC; Lee JM Front Oncol; 2014; 4():42. PubMed ID: 24616882 [TBL] [Abstract][Full Text] [Related]
10. Poly (ADP-ribose) polymerase inhibitors in solid tumours: Systematic review and meta-analysis. Schettini F; Giudici F; Bernocchi O; Sirico M; Corona SP; Giuliano M; Locci M; Paris I; Scambia G; De Placido S; Rescigno P; Prat A; Curigliano G; Generali D Eur J Cancer; 2021 May; 149():134-152. PubMed ID: 33862496 [TBL] [Abstract][Full Text] [Related]
12. An Effective Epigenetic-PARP Inhibitor Combination Therapy for Breast and Ovarian Cancers Independent of BRCA Mutations. Pulliam N; Fang F; Ozes AR; Tang J; Adewuyi A; Keer H; Lyons J; Baylin SB; Matei D; Nakshatri H; Rassool FV; Miller KD; Nephew KP Clin Cancer Res; 2018 Jul; 24(13):3163-3175. PubMed ID: 29615458 [No Abstract] [Full Text] [Related]
13. The Role of PARP Inhibitors in the Treatment of Prostate Cancer: Recent Advances in Clinical Trials. Xia M; Guo Z; Hu Z Biomolecules; 2021 May; 11(5):. PubMed ID: 34066020 [TBL] [Abstract][Full Text] [Related]
15. PARP Inhibitors Display Differential Efficacy in Models of Dickson KA; Xie T; Evenhuis C; Ma Y; Marsh DJ Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445211 [TBL] [Abstract][Full Text] [Related]
16. BRCA1/2 testing: therapeutic implications for breast cancer management. Tung NM; Garber JE Br J Cancer; 2018 Jul; 119(2):141-152. PubMed ID: 29867226 [TBL] [Abstract][Full Text] [Related]
17. Poly (ADP-ribose) Polymerase Inhibition in Patients with Breast Cancer and BRCA 1 and 2 Mutations. Jerez Y; Márquez-Rodas I; Aparicio I; Alva M; Martín M; López-Tarruella S Drugs; 2020 Feb; 80(2):131-146. PubMed ID: 31823331 [TBL] [Abstract][Full Text] [Related]
18. Resurrection of PARP Inhibitors in Breast Cancer. Lyons TG; Robson ME J Natl Compr Canc Netw; 2018 Sep; 16(9):1150-1156. PubMed ID: 30181424 [TBL] [Abstract][Full Text] [Related]
19. EZH2 contributes to the response to PARP inhibitors through its PARP-mediated poly-ADP ribosylation in breast cancer. Yamaguchi H; Du Y; Nakai K; Ding M; Chang SS; Hsu JL; Yao J; Wei Y; Nie L; Jiao S; Chang WC; Chen CH; Yu Y; Hortobagyi GN; Hung MC Oncogene; 2018 Jan; 37(2):208-217. PubMed ID: 28925391 [TBL] [Abstract][Full Text] [Related]
20. Movement of Poly-ADP Ribose (PARP) Inhibition into Frontline Treatment of Ovarian Cancer. Onstad M; Coleman RL; Westin SN Drugs; 2020 Oct; 80(15):1525-1535. PubMed ID: 32852746 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]